Sarepta Therapeutics (SRPT) PT Raised to $160 at BTIG 'on Our Conviction on SRP-9001's FDA Approval'
Tweet Send to a Friend
(Updated - December 21, 2022 1:33 PM EST)
BTIG analyst Yun Zhong raised the price target on Sarepta Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
BTIG analyst Yun Zhong raised the price target on Sarepta Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
